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Background: Urea injection has been used in hemangioma treatment as sclerotherapy. It shrinks vascular
endothelial cells and induces degeneration, necrosis, and fibrosis. However, this treatment still has disadvantages,
such as lacking targeting and difficulty in controlling the urea dosage. Thus, we designed a urea immunoliposome
to improve the efficiency of treatment.
Methods: The urea liposome was prepared by reverse phase evaporation. Furthermore, the urea immunoliposome
was generated by coupling the urea liposome with a vascular endothelial growth factor receptor (VEGFR)
monoclonal antibody using the glutaraldehyde cross-linking method. The influence of the urea immunoliposome
on cultured human hemangioma vascular endothelial cells was observed preliminarily.
Results: Urea immunoliposomes showed typical liposome morphology under a transmission electron microscope,
with an encapsulation percentage of 54.4% and a coupling rate of 36.84% for anti-VEGFR. Treatment with the urea
immunoliposome significantly inhibited the proliferation of hemangioma vascular endothelial cells (HVECs) in a
time- and dose-dependent manner.
Conclusions: The urea immunoliposome that we developed distinctly and persistently inhibited the proliferation of
HVECs and is expected to be used in clinical hemangioma treatment.
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Hemangioma is the most common benign tumor of
infancy and is characterized by vascular endothelial
cell proliferation. Because its predilection sites are always
on the body surface, especially in the maxillofacial region,
hemangioma seriously affects patients’ appearance and
physiological function, and even induces mental stress and
psychological disorders [1,2]. Urea injection has long been
used in the treatment of hemangioma in our hospital
as a type of sclerotherapy, particularly in refractory and
recurrent cases [3-5]. Urea can shrink hemangioma
endothelial cells to induce degeneration, necrosis, and
fibrosis. This treatment has shown obvious therapeutic
effects, even cures. However, it still presents several
disadvantages: urea injection is not targeted, and its dosage* Correspondence: paul5381@sina.com
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reproduction in any medium, provided the oris difficult to control: too high a dose would induce local
necrosis, ulceration, and infection, ultimately inducing
scars and developmental disorders; too low a dose would
not induce an obvious effect and would prolong the
treatment cycle. Inappropriately high local urea doses
have also induced other complications [3].
Vascular endothelial growth factor (VEGF) and its
receptor (VEGFR) have been reported to be crucial in
vasculogenesis and angiogenesis. They are closely related
with the pathology of hemangioma [6-8]. VEGF is secreted
from vascular endothelial cells (VECs), as well as some
non-endothelial cells. Levels of VEGF are increased in
proliferative hemangioma specimens and decreased in
paracmastic specimens [2]. As a specific mitogen of
vascular endothelial cells, VEGF binds to VEGFR on VECs
and promotes endothelial cell mitosis, proliferation, and
migration, and the formation of new vessels in cooperation
with non-endothelial cells.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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consisted of encapsulated urea with liposomes [9,10]
coupled with an anti-VEGFR antibody. The liposome is
designed to protect the urea, delay its degradation, and
help its incorporation into human hemangioma vascular
endothelial cells (HVECs). The coupled VEGFR monoclo-
nal antibody ensures the targeting of urea to VECs, in
order to improve the efficacy of urea and reduce the
complications of urea injection. The influence of our




The urea liposome was prepared by reverse phase evap-
oration. Soybean phospholipid (Taiwei, Shanghai, China)
and cholesterol (Yansheng, Shanghai, China) were first
mixed at a weight ratio of 4:1 and dissolved in 5 ml of ethyl
ether. Subsequently, 2.4 g of urea (the Second Affiliated
Hospital of Medical College, Xi’an Jiaotong University)
and 5 ml of distilled water were added. They were mixed
ultrasonically for 10 min until a stable water/oil emulsion
was formed. The ether was then removed by vacuum at
25°C. Five milliliters of distilled water were added, and
the resultant mixture was successively filtered through
0.8 μm and 0.45 μm membranes. Finally, 10 ml of 24%
urea liposome was prepared and stored at 4°C for use.
Encapsulation percentage determination
Five hundred microliters of urea liposome were loaded on
the top of a Sephadex-50 column (Pharmacia, Philadelphia,
PA) and eluted with deionized water. The eluate was
successively collected into ten tubes, 3 ml in each tube, at
a dropping rate of 1 ml/min. Chromatography was per-
formed at room temperature and developed by paradi-
methylaminobenzaldehyde for 10 min. The absorbance
values of each eluate were determined using a spectropho-
tometer at a wavelength of 440 nm. The encapsulation
percentage of the urea liposome was calculated with the
formula:
encapsulation percentage %ð Þ
¼ quantity of urea encapsulated in lipsome
quantity of total urea
 100%
Urea immunoliposome preparation
Twenty-five microliters of 25% glutaraldehyde was added
to 1 ml of 24% urea liposome, and the mixture was
maintained at 20°C for 10 min. The excess glutaraldehyde
was removed by saline dialysis for 2 h. Subsequently, the
saline was exchanged for fresh saline containing 0.5 mg
of anti-VEGFR2 (R&D systems, Minneapolis, MN), and the
dialysis proceeded overnight at 4°C. After sterilization by
60Co irradiation, 24% urea immunoliposome was prepared
and stored at 4°C for use.Coupling rate determination
The urea immunoliposomes were separated via six sepa-
rations by sucrose density gradient centrifugation. The
phospholipid and protein contents in each separation were
determined by the molybdenum blue and Coomassie
methods, respectively. The second separation contained
both lipids and proteins. Only proteins were detected in
the fifth and sixth separations. Thus, the second separation,
which contained both lipids and protein, harbored the
immunoliposomes composed of anti-VEGFR coupled
with the urea liposome. The coupling rate of the urea
immunoliposome was calculated with the formula:
coupling rate %ð Þ
¼ content of anti‐VEGFR coupled with uread lipsome
initial content of anti‐VEGFR
 100%
Morphology of urea immunoliposome was observed by
transmission electron microscopy
A 24% urea immunoliposome solution was separately
diluted 10 times and 100 times. One drop of each dilution
was added to a Form wan copper net and stained nega-
tively by 2% phosphotungstic acid. After drying at room
temperature, the nets were examined with an electron
microscope (TEM-2000EX, JEOL, Japan).
Hemangioma vascular endothelial cell preparation
and culture
The experiment was approved by the ethics committees of
Xi’an Jiaotong University School of Medicine. Informed
consent was obtained from all patients. Resected tissue
obtained from surgery on children aged 59 days suffering
from strawberry hemangioma on the abdominal surface
was selected to isolate the HVECs for tissue culture.
The hemangiomas were cut into small pieces, inoculated
into culture flasks, and maintained in DMEM medium
(GIBCO, NY) supplemented with 10% FBS (Sijiqing,
Hangzhou, China) at 37°C in a humidified atmosphere of
5% CO2 and 95% air. After 3 days, the endothelial cells
quickly migrated from the tissue pieces. One week later,
some endothelial cells became confluent. After removing
the tissue pieces, the endothelial cells formed a monolayer,
covering the bottom of the flask after approximately
3 weeks. They were then subcultured by trypsin digestion
and grew actively as the number of passages increased.
Compared with primary cells, endothelial cells showed a
more stretched, spindle-like morphology after several
passages, but still grew in a monolayer. They were cultured
in vitro for approximately 6 months. The HVECs we
isolated and cultured were identified by HVEC factor
VIII related antigen (VIII-R Ag) immunostaining and
VEGFR2 flow cytometry.
For the immunostaining with VIII-R Ag, subcultured
endothelial cells were inoculated on a cover glass and
Figure 1 Urea immunoliposome morphology. (A) Both the
urea liposome and urea immunoliposome generated a
suspension that appeared milky white upon gross inspection.
(B) Urea immunoliposomes diluted 100 times observed under a
transmission electron microscope (×150,000).
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to reduce endogenous peroxidase activity. After blocking
with normal goat serum, they were then incubated with
anti-VIII-R Ag (1:50 dilution, ZSBIO, Beijing, China),
followed by an incubation with secondary antibody conju-
gated with biotin (ZSBIO) and development with ABC
(ZSBIO) and diaminobenzidine reagent (Boster, Wuhan,
China). Digital images were obtained using a Leica Photo
Microscope (Q550CW, Leica, Germany).
For VEGFR flow cytometry, subcultured endothelial cells
were suspended in cold culture medium at a density of
5 × 106 cells per milliliter. Forty microliters of cell suspen-
sion were mixed with anti-VEGFR2 and maintained at 4°C
for 30 min. After washing, they were incubated with
secondary antibody conjugated with fluorescein isothio-
cyanate (Boster) at 4°C for 30 min. The cells were ana-
lyzed with an automated fluorescence-activated cell counter
(Elite, Beckman Coulter), with which 1,000,000 events
were counted. The absolute number of cells expressing
VEGFR2 per 1,000,000 events was calculated, and the
percentage was derived.
Influence of urea immunoliposome on human vascular
endothelial cell morphology
The HVECs were passaged in 96-well plates at a density
of 4 × 103 cells per well. Twenty-four hours later, the
urea immunoliposomes diluted with culture medium were
added to each well at different final concentrations of 0,
0.002%, 1%, 2%, 3%, 4%, 5%, 10%, 20%, or 40%. Four
wells were seeded per concentration. Changes in HVEC
morphology were observed under an inverted phase con-
trast microscope (IMT-2, Olympus, Japan) after 24 h, 48 h,
and 72 h.
Influence of urea immunoliposome on human vascular
endothelial cell proliferation
The HVECs were passaged in 96-well plates at a density
of 2 × 103 cells per well. Twenty-four hours later, urea
immunoliposomes diluted with culture medium were added
to each well at the same final concentrations, mentioned
previously. After 24, 48, and 72 hours, the proliferation
of HVECs was measured by the MTT method (Sigma)
according to the manufacturer’s protocols. The median
influence dose (ID50) was calculated by linear regression
analysis.
The HVECs were passaged in 24-well plates at a
density of 1 × 104 cells per well. Twenty-four hours
later, the cells were divided into five groups: three ex-
perimental groups treated with 2.6% urea, 2.6% urea
liposome, or 2.6% urea immunoliposome, and two con-
trol groups, treated with the same volume of liposome or
culture medium, at four wells per group. Subsequently,
the number of HVECs in each group was counted
every day for 8 days. A growth curve was generated andthe population doubling time was calculated using the
following formula:
doubling time ¼ t  log2= logNt − logN0ð Þ
where t represents the culture period during which the
cell grows in the log phase; N0 is the cell number of
cells at the start of the log phase; and Nt is the cell
number at the end of the log phase. On the eighth day,
the cell numbers of each group were used to calculate
the inhibition rate:
inhibition rate %ð Þ
¼ cell number of control group−cell number of experimental groupð Þ
cell number of control group
 100%
Data analysis
Data are expressed as the mean ± standard errors of the
mean with the number of individual experiments described
in the figure legends. The differences between groups were
analyzed using Student’s t test. P < 0.05 was considered
statistically significant.
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Urea immunoliposome characteristics
Both the urea liposome and urea immunoliposome formed
a milky white suspension on gross examination, as shown
in Figure 1A, which remained stable and did not obviously
change in appearance for 6 months at 4°C. The urea
immunoliposomes diluted 100 times showed a typical
liposome morphology under a transmission electron micro-
scope, as shown in Figure 1B. The urea immunoliposomes
were spherical or near spherical, large unilamellar liposomesFigure 2 Hemangioma vascular endothelial cell (HVEC) culture and id
the surgery of children aged 59 days who had strawberry hemangioma on
inoculated into culture flasks, and maintained in culture medium. After 3 d
week later, some of the endothelial cells became confluent (×100). (B) The
related antigen (VIII-R Ag) immunostaining (×200). (C) The HVECs were also
cells that we isolated and subcultured was 59.1%.with a diameter of 150 to 200 nm. A nucleolar structure
and lipid-coating structure were obvious. The encapsula-
tion percentage of urea liposomes was 54.4%, according to
Sephadex-50 column elution analysis. The coupling rate of
anti-VEGFR to urea immunoliposomes was 36.84%.
Preparation and culture of hemangioma vascular
endothelial cells
The HVECs were isolated by tissue culture. Approximately
3 days after inoculation, the endothelial cells migratedentification. (A) The HVECs were derived from tissues resected during
the abdominal surface. The tissues were cut into small pieces,
ays, the endothelial cells migrated quickly from the tissue pieces. One
HVECs were identified with human vascular endothelial cells factor VIII
analyzed with VEGFR2 flow cytometry. The percentage of HVECs in
Table 1 The proliferation of HVECs was inhibited by urea, urea liposome, and urea immunoliposome treatment
Culture period (day) Cell number (X ± S, ×104)
Medium Liposome 2.6% urea 2.6% urea liposome 2.6% urea immunoliposome
0 1.00 ± 0.15 1.00 ± 0.14 1.00 ± 0.05 1.00 ± 0.28 1.00 ± 0.24
1 3.90 ± 0.19 3.62 ± 0.17 5.00 ± 0.26 2.25 ± 0.11* 1.75 ± 0.09**
2 5.43 ± 0.45 5.89 ± 0.24 6.30 ± 0.86 4.64 ± 0.32* 1.40 ± 0.11***
3 11.6 ± 0.50 10.25 ± 0.72 9.98 ± 0.28 5.16 ± 0.64** 1.40 ± 0.07***
4 16.01 ± 0.92 17.50 ± 1.12 16.19 ± 1.38 6.56 ± 1.02*** 0.86 ± 0.04***
5 25.73 ± 1.07 26.5 ± 2.41 22.31 ± 1.15* 9.10 ± 0.52*** 0.27 ± 0.03***
6 34.65 ± 1.73 34.25 ± 1.42 27.30 ± 2.13* 10.24 ± 0.73*** 0.19 ± 0.01***
7 46.50 ± 3.57 42.60 ± 4.21 32.46 ± 2.45** 8.14 ± 0.23*** 0.08 ± 0.0038***
8 47.6 ± 2.10 45.00 ± 3.20 34.30 ± 3.30** 7.61 ± 0.003*** 0.04 ± 0.0021***
HVECs were treated as in Figure 3. The daily cell numbers are shown as the mean ± standard error in the mean and are representative of three independent
experiments. *P < 0.05; **P < 0.01; ***P < 0.0001, compared with the control.
Figure 3 Urea immunoliposome induced inhibition of
hemangioma vascular endothelial cell (HVEC) proliferation.
HVECs were passaged in 24-well plates at a density of 1 × 104 cells
per well. Twenty-four hours later, the cells were divided into five
groups: three experimental groups treated with 2.6% urea, 2.6% urea
liposome, or 2.6% urea immunoliposome, and two control groups
treated with the same volume of liposome or normal medium at four
wells per group. The number of cultured HVECs was subsequently
counted every day for 8 days. The data are representative of three
independent experiments.
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structure, clear boundaries, abundant cytoplasm, and
central round or oval nuclei. One week later, some of
the endothelial cells became confluent (Figure 2A). After
removing the tissue pieces, the endothelial cells grew as a
monolayer, covering the bottom of the flask approximately
3 weeks later. They were then subcultured by trypsin
digestion and grew actively as the number of passages
increased. Compared with primary cells, endothelial
cells were more stretched and spindle-like after several
passages, but still grew in a monolayer. Immunostaining
with VIII-R Ag showed that the cells that we isolated and
subcultured were positively stained (Figure 2B). The data
obtained from the VEGFR2 flow cytometry indicated
that the percentage of HVECs in cells we isolated and
subcultured was 51.9% (Figure 2C), which was identical to
the figures reported in previous reports [2].
Influence of urea immunoliposome on HVEC proliferation
The HVECs were damaged by urea immunoliposome at
a concentration of 40% and instantly died. The treatment
time did not obviously influence the other groups. Twenty-
four hours later, most of the HVECs treated with 10% and
20% urea immunoliposome were dead, and HVECs treated
with 5% urea immunoliposome were beginning to die. The
other treatment groups did not show signs of cell death.
Forty-eight hours later, some of the HVECs treated with
1%, 2%, 3%, and 4% urea immunoliposome were dead and
continued to die as the treatment time was extended. The
HVECs treated with 0.002% urea immunoliposome did not
show obvious changes during the entire 72 hours compared
with the control. The proliferation of HVECs was inhibited
by urea immunoliposomes, and the ID50 was obtained from
the linear regression equation:
ID50 ¼ 1:4024–1:368 50%ð Þ=0:02756 ¼ 2:6%:Cell proliferation was inhibited by 2.6% urea, 2.6% urea
liposome, and 2.6% urea immunoliposome, as shown in
Table 1 and Figure 3. The HVECs in the urea immunoli-
posome group were most influenced, followed by the urea
liposome group, and the urea group. The two control
groups, HVECs treated with culture medium or liposomes,
did not show obvious differences. Compared with the
control, the inhibition rate of HVEC proliferation on
the 8th day was 99.91% in the urea immunoliposome
group, 84.01% in the urea liposome group, and 27.94%
in the urea group. The population doubling time in the
medium, liposome, urea, and urea liposome groups were
43.1 h, 49.5 h, 63.7 h, and 74.4 h, respectively. The doubling
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group, owing to the severely inhibited proliferation.
Discussion
Urea injection has been used to treat hemangioma in
our hospital as a type of sclerotherapy. Urea can shrink
hemangioma endothelial cells to induce degeneration,
necrosis, and fibrosis. However, this treatment still features
disadvantages, such as a lack of targeting and difficulty
in controlling the urea dosage. Thus, we designed a urea
immunoliposome that consisted of urea encapsulated with
a liposome that was coupled with a VEGFR monoclonal
antibody. Encapsulating urea with a liposome allows the
urea to incorporate into the cell more easily via lipid
fusion. Furthermore, coupling with anti-VEGFR ensures
that the urea selectively acts on VECs, to improve the
efficiency of urea against hemangioma. Indeed, urea
immunoliposomes significantly inhibited the proliferation
of HVECs compared with urea or urea liposome (Table 1
and Figure 3).
The encapsulation rate is an important quality index of
liposomes [11,12]. Liposome encapsulation is influenced
by many factors, such as the drug’s solubility, lipid com-
position, the ratio of drug to lipid, and the ratio of oil to
water when the liposome contains a water-soluble drug.
The conditions were determined according to previous ex-
periments to produce the urea liposomes: a phospholipid:
cholesterol ratio of 4:1; a urea: lipid ratio of 1:60; and an
oil: water ratio of 5:1. The urea liposomes showed a large
unilamellar structure (Figure 1B), and the encapsulation
percentage was 54.4%, which was slightly better than
the figures reported by previous studies [11]. The coupling
rate is an important index that reflects the quality of the
immunoliposome. It is also influenced by many factors,
including the coupling method, antibody type, and lipo-
some quality [13]. The coupling rate of anti-VEGFR to
the urea immunoliposome was 36.84%; it is expected that
this can be further improved by optimizing the coupling
conditions.
The etiology and development of hemangioma have not
been elucidated [14]. Only some proteins and polypeptide
growth factors have been reported to play important roles
in the pathophysiology of hemangioma. Both VEGF and
VEGFR are reportedly closely involved in the pathology
of hemangioma. In our experiments, treatment with urea
immunoliposome coupled with anti-VEGFR significantly
inhibited the proliferation of HVECs: the inhibition rate
was 99.91% on the 8th day and the doubling time could
not be determined. Although treatment with urea liposome
inhibited the proliferation of HVECs more than urea
treatment due to the protection of urea by the liposome,
its inhibition was less pronounced than that of the urea
immunoliposome. We thought that in addition to targeting
urea to HVECs, the anti-VEGFR antibody coupled to theurea immunoliposome could also block the effect of VEGF
and induce death and atrophy in HVECs.
Recently, targeted therapy has been increasingly devel-
oped and applied to cancer therapy [15]. The inhibition of
HVECs by urea immunoliposome has not been reported
to date. The urea immunoliposome we developed has
several advantages: urea encapsulated by liposome is more
easily incorporated in HVECs; anti-VEGFR ensures the
targeting of urea to HVECs in order to exert cytotoxicity
on only these cells; and anti-VEGFR also blocks the effect
of VEGF on HVECs to induce apoptosis and atrophy. The
use of urea immunoliposomes resulted in the distinct and
persistent inhibition of HVEC proliferation and could be
used to treat hemangioma in the clinic.
Conclusions
The urea immunoliposome we developed distinctly and
persistently inhibited the proliferation of HVECs and can
potentially be used in clinical hemangioma treatment.
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